RBC Capital Preview Lam Research (LRCX), Says "Don't Get Altitude Sickness Yet", Expects Positive Report

January 24, 2017 4:00 AM

RBC Capital maintains Outperform on Lam Research (NASDAQ: LRCX), keeps price target of $120.00.Analyst Amit Daryanani comments "LRCX is positioned ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found